IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A recording of this discussion is accessible on the company’s website in the Investors section and will be available for 90 days. IGM Biosciences focuses on developing engineered IgM antibodies and has made significant advancements since 2010 in overcoming challenges related to their therapeutic use.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was +0.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
A recording of the fireside chat is now available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations and will be available for 90 days.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.